-
公开(公告)号：US20190328735A1
公开(公告)日：2019-10-31
申请号：US16172368
申请日：2018-10-26
Applicant: Cephalon, Inc.
Inventor： Shawn P. Allwein , Laurent Courvoisier , Martin J. Jacobs , Gregory R. Ott
IPC: A61K31/506 , C07D403/04
Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
-
公开(公告)号：US20190308934A1
公开(公告)日：2019-10-10
申请号：US16449612
申请日：2019-06-24
Applicant: CEPHALON, INC.
Inventor： Ralph Laufer , Gregory R. Ott
IPC: C07C271/22 , C07C233/05 , C07C271/28 , C07C305/12 , C07D207/09 , C07D223/16 , C07D263/18 , C07F9/09 , A61K31/165 , A61K31/18 , A61K31/196 , A61K31/198 , A61K31/216 , A61K31/24 , A61K31/255 , A61K31/325 , A61K31/40 , A61K31/421 , A61K31/55 , A61K31/661 , A61K31/7028 , A61K38/03 , C07K4/00 , C07C233/36 , C07D207/08 , C07H13/04 , C07D223/12 , C07C237/20 , C07C233/54 , C07C233/51 , C07C229/42 , C07C311/51 , C07C233/47
Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.
-
公开(公告)号：US10259794B2
公开(公告)日：2019-04-16
申请号：US15537954
申请日：2015-12-23
Applicant: CEPHALON, INC.
Inventor： Shawn P. Allwein , Roger P. Bakale , Dale R. Mowrey , Daniel E. Petrillo , Sander Kluwer
IPC: C07D241/04 , C07D295/135 , C07D403/12 , A61K31/495
Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
-
公开(公告)号：US20190062421A1
公开(公告)日：2019-02-28
申请号：US16112016
申请日：2018-08-24
Applicant: Cephalon, Inc.
Inventor： Parameswaran Nair , Manali Mukherjee
Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.
-
公开(公告)号：US20180030131A1
公开(公告)日：2018-02-01
申请号：US15783289
申请日：2017-10-13
Applicant: Cephalon, Inc.
Inventor： Christopher Obrien , James Zangrilli , Tushar Shah , Guy Brusselle
Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL.
-
Patent Agency Ranking
公开(公告)号：US20180021696A1
公开(公告)日：2018-01-25
申请号：US15659093
申请日：2017-07-25
Applicant: Cephalon, Inc.
Inventor： Lu WANG , Tim ZHOU , Zhaoqing ZHANG , Mi JIN
IPC: B01D15/38 , C07K14/555 , C07K16/18 , C07K1/22 , C07K16/28
Abstract: A wash buffer comprising greater than 0 mM and less than about 500 mM arginine, greater than 0 mM and less than about 250 mM guanidine, greater than 0 mM and less than about 250 mM sodium chloride, and greater than 0 mM and less than about 50 mM of an anionic surfactant, or greater than 0% and less than about 0.25% w/v of a non-ionic surfactant. When used during affinity chromatography purification of a protein of interest, such as an antibody, the wash buffer significantly reduces the level of host cell proteins from the preparation. Following affinity chromatography with the wash buffer, the protein of interest may be further purified using membrane chromatography.
-
公开(公告)号：US20170143640A1
公开(公告)日：2017-05-25
申请号：US15425421
申请日：2017-02-06
Applicant: Cephalon, Inc.
Inventor： Peter D. Brown , Anthony S. Drager
IPC: A61K9/51 , A61K9/50 , A61K31/4184 , A61K38/02 , A61K31/7088
CPC classification number: A61K9/5146 , A61K9/145 , A61K9/5031 , A61K9/5089 , A61K31/4184 , A61K31/7088 , A61K38/02 , A61K47/60 , A61K47/6935 , C07D235/16
Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
-
公开(公告)号：US20170071913A1
公开(公告)日：2017-03-16
申请号：US15359777
申请日：2016-11-23
Applicant: Cephalon, Inc.
IPC: A61K31/4184 , A61K47/26 , A61K9/00
CPC classification number: A61K31/4184 , A61K9/0019 , A61K9/14 , A61K9/19 , A61K47/26 , C07D235/16
Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
Abstract translation: 描述了新型固体形式的盐酸苯达莫司汀，以及它们的制备和使用方法。
-
公开(公告)号：US20170027948A1
公开(公告)日：2017-02-02
申请号：US15292468
申请日：2016-10-13
Applicant: Cephalon, Inc.
Inventor： Henry J. Breslin , Bruce D. Dorsey , Gregory R. Ott
IPC: A61K31/529 , A61K31/5377
CPC classification number: A61K31/529 , A61K31/5377 , C07D487/08 , C07D487/18
Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
Abstract translation: 或其药学上可接受的盐形式，其中R 1，R 2，R 3，R 4，R 5，A和X如本文所定义，其处理方法及其用途。
-
公开(公告)号：US20160347756A1
公开(公告)日：2016-12-01
申请号：US15232084
申请日：2016-08-09
Applicant: Cephalon, Inc.
Inventor： Ralph C. Haltiwanger , Eugen F. Mesaros , Gregory R. Ott
IPC: C07D487/04
CPC classification number: C07D487/04 , A61K31/53
Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
Abstract translation: 和/或其盐，其中X，R 1和R 2如本文所定义。 还描述了组合物和治疗用途。
-
-
-
-
-
-
-
-
-
Search Results
134
records
(took 0.027 seconds)
